SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-18-160070
Filing Date
2018-05-11
Accepted
2018-05-11 08:07:00
Documents
58
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d463470d10q.htm 10-Q 837866
2 EX-31.1 d463470dex311.htm EX-31.1 9091
3 EX-31.2 d463470dex312.htm EX-31.2 9086
4 EX-32.1 d463470dex321.htm EX-32.1 4227
5 EX-32.2 d463470dex322.htm EX-32.2 4222
  Complete submission text file 0001193125-18-160070.txt   4345259

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT dnli-20180331.xml EX-101.INS 777385
7 XBRL TAXONOMY EXTENSION SCHEMA dnli-20180331.xsd EX-101.SCH 49881
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE dnli-20180331_cal.xml EX-101.CAL 52355
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dnli-20180331_def.xml EX-101.DEF 194994
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE dnli-20180331_lab.xml EX-101.LAB 419858
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dnli-20180331_pre.xml EX-101.PRE 299549
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 18824954
SIC: 2836 Biological Products, (No Diagnostic Substances)